Galectin Therapeutics Inc. CEO & President & Chief Medical Officer Peter G. Traber Resigned

Galectin Names Shlevin as New CEO; Traber Resigns

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold H. Shlevin, Ph.D., currently the Company’s Chief Operating Officer (COO), has been appointed Chief Executive Officer (CEO) and President to succeed Peter G. Traber, M.D., who has tendered his resignation as President, CEO and Chief Medical Officer.

Name: Peter G. Traber

Continent: North America

Country: USA

Company: Galectin Therapeutics Inc.

Branch: Healthcare

Position: CEO & President & Chief Medical Officer

Reason: Resigned

Announcement Date: June 12, 2018, 10:00pm

Resignation Date: June 12, 2018, 10:00pm

Source 1: https://awesomecapital.wordpress.com/2018/06/13/galectin-names-shlevin-as-new-ceo-traber-resigns/